Shanghai Zhongshan Hospital: Carcinoma, Hepatocellular trials

The registry lists 61 Carcinoma, Hepatocellular studies with Shanghai Zhongshan Hospital as lead sponsor. 26 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 24Phase 3 9No phase 28(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCNot yet recruitingNCT07786792
• Different Acupoint Stimulation for Postoperative Gastrointestinal Dysfunction in Primary Liver Cancer PatientsNot yet recruitingNCT07781176Not applicable
• Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular CarcinomaNot yet recruitingNCT07734857
• The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951
• Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Not yet recruitingNCT07714317Phase 1/2
• AI-Driven Tumor Response Evaluation for Solid TumorsNot yet recruitingNCT07685548
• PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative HepatectomyNot yet recruitingNCT07644208Phase 2
• A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07309419Phase 2/3
• Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort StudyNot yet recruitingNCT07206511
• Clinical Trials of the Hepatitis B Sandwich Combination Therapy for Treating Patients Infected With Hepatitis B VirusNot yet recruitingNCT07088133Not applicable
• A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular CancerNot yet recruitingNCT06935175Phase 2
• Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 TherapyRecruitingNCT06870942Phase 2
• Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)RecruitingNCT06796803Phase 2/3
• Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical StudyRecruitingNCT06794073Not applicable
• Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCCNot yet recruitingNCT06639971
• Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCCRecruitingNCT06537908
• Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT06530784Phase 2
• PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7Not yet recruitingNCT06423144
• Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion TherapyRecruitingNCT06382103
• Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsNot yet recruitingNCT06031480Phase 2
• Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With SurgeryRecruitingNCT05970159
• M-TACE Treatment for Unresectable Hepatocellular CarcinomaEnrolling by invitationNCT05875558Not applicable
• Clinical Study of mRNA Vaccine in Patients With Liver Cancer After OperationNot yet recruitingNCT05761717Not applicable
• Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular CarcinomaRecruitingNCT05701553
• Prognostic Performance of Preoperative and Follow by Gadoxetic Enhanced MRI in HCC Patients After TACENot yet recruitingNCT05125094
• Camrelizumab in Patients With Unresectable Hepatocellular CarcinomaNot yet recruitingNCT04947956
• Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Phase 2
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2
• A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT05363722Phase 1
• A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCCStatus unknownNCT05205629
• A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical PracticeStatus unknownNCT05200221
• Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular CarcinomaStatus unknownNCT05087459
• Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCCStatus unknownNCT05056337Phase 3
• Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor ThrombosisStatus unknownNCT04947826Phase 2
• Adjuvant Therapy With Anlotinib for HCCWithdrawnNCT04947371Phase 2
• Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCCStatus unknownNCT04943679
• Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04926532Phase 1/2
• Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTStatus unknownNCT04850157Phase 2
• Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284
• Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
• TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Phase 2
• Study of TACE Combined With Camrelizumab in the Treatment of HCC PatientsActive, not recruitingNCT04483284Phase 2
• Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCCStatus unknownNCT04241523Phase 2
• A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular CarcinomaStatus unknownNCT04239781
• Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Phase 2
• Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.Active, not recruitingNCT04220944Phase 1
• Study of Anlotinib After Lenvatinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04080154Phase 2
• SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04014101Phase 2
• Safety and Efficacy of PD-1 Inhibitors in Patients With Liver TransplantStatus unknownNCT03966209Phase 1
• A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor ThrombiStatus unknownNCT03939845Phase 3
• Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular CarcinomaStatus unknownNCT03857815Phase 2
• SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryStatus unknownNCT03722875Not applicable
• Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular CarcinomaStatus unknownNCT03510416Phase 2
• Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine TestStatus unknownNCT03493763
• A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular CarcinomaStatus unknownNCT03416803Not applicable
• Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical ResectionStatus unknownNCT03261791Phase 2
• A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCCStatus unknownNCT03116984Phase 3
• Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor ThrombusStatus unknownNCT02971345Phase 3
• Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver CancerStatus unknownNCT02644603Not applicable
• TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular CarcinomaStatus unknownNCT02630108Phase 3
• Combination Treatment for Advanced Liver CancerWithdrawnNCT02149771Phase 3